![Deshpande Wiesler Deshpande Wiesler](/sites/default/files/2024-08/Website_OhneLogo.jpg)
August 30, 2024
Boehringer Ingelheim announces appointments Board of Managing Directors
![Boehringer_Workplace_Lab_Research-01 Boehringer_Workplace_Lab_Research-01](/sites/default/files/2024-08/Boehringer_Workplace_Lab_Research-01_RGB_010.jpg)
August 27, 2024
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC
![Boehringer Ingelheim acquires Nerio Therapeutics in the lab](/sites/default/files/2024-07/Nerio.png)
July 29, 2024
Boehringer Ingelheim acquires Nerio Therapeutics
![CHMP-positive-opinion-SPEVIGO CHMP-positive-opinion-SPEVIGO](/sites/default/files/2024-07/CHMP-positive-opinion-SPEVIGO.jpg)
July 29, 2024
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
![Boehringer_Workplace_Lab_Research Boehringer_Workplace_Lab_Research](/sites/default/files/2024-07/Boehringer_Workplace_Lab_Research-01_CMYK_001%20resized.png)
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
![Ingelheim biomass plant inauguration cropped Ingelheim biomass plant inauguration cropped](/sites/default/files/2024-07/0O9A7814Bearb_cropped.jpg)
July 08, 2024
Boehringer Ingelheim produces its own green energy
![Boehringer Ingelheim advances SIRP immune-oncology program Pipettes with violet fluid](/sites/default/files/2024-07/PR_OSE2.jpg)
July 03, 2024
Boehringer Ingelheim advances SIRPα immuno-oncology program
![Phase 1 start for novel triple agonist obesity treatment Woman working in the lab on a laptop](/sites/default/files/2024-07/PR_Grupa.jpg)
July 01, 2024
Phase 1 start for novel triple agonist obesity treatment
![3-Lab-techs 3-Lab-techs](/sites/default/files/2024-06/3-Lab-techs-v2%20%281%29.png)
June 07, 2024
Survodutide shows breakthrough improvement in liver fibrosis
![Boehringer Ingelheim Economist Impact Boehringer Ingelheim Economist Impact](/sites/default/files/2024-05/Boehringer_Lifestyle_SocialLife_MeetingFriends-01_CMYK_018.png)
May 28, 2024
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
![Man in the lab Man working in the lab](/sites/default/files/2024-05/PR_OSE.jpg)
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
![Sheep with bell are looking at camera Sheep with bell are looking at camera](/sites/default/files/2024-05/Bultavo%20press%20release.jpg)
May 13, 2024
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3)
![Hornbill Press Release Woman in the lab](/sites/default/files/2024-05/HornbillPR.jpg)
May 06, 2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
![Veterinarian treats dog, chicken is being held in barn Veterinarian treats dog, chicken is being held in barn](/sites/default/files/2024-04/Veterinarian%20treats%20dog%2C%20chicken%20is%20being%20held%20in%20barn.jpg)
April 25, 2024
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated
![boehringer_biopharmaceutical production_Biberach boehringer_biopharmaceutical production_Biberach](/sites/default/files/2024-04/boehringer_biopharmaceutical%20production_Biberach%20resized.jpg)
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 09, 2024
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
![EMPA EMPA](/sites/default/files/2024-04/EMPA%20image.png)
April 06, 2024
Results announced from EMPACT-MI phase III trial
![Boehringer Workplace Lab Research Boehringer Workplace Lab Research](/sites/default/files/2024-03/Boehringer_Workplace_Lab_Research-01_RGB_003%20%281%29.jpg)
March 19, 2024
SPEVIGO® approved for expanded indications in China and the US
![Boehringer_Lifestyle_SocialLife_MeetingFriends Two persons talking](/sites/default/files/2024-03/Boehringer_Lifestyle_SocialLife_MeetingFriends-01_RGB_008.jpg)
March 11, 2024
New partnership to develop schizophrenia treatments
![MASH MASH](/sites/default/files/2024-03/MASH_klein_1_0.png)
February 26, 2024
Survodutide Phase II trial shows groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
![Girl with horse in front of a camera](/sites/default/files/2024-02/Sleip_Partnership_website.png)
February 19, 2024
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
![doctor pointing on spine](/sites/default/files/2024-02/CBmed.jpg)
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
![Employee in learning environment](/sites/default/files/2024-01/Untitled%20design%20%281%29.png)
January 18, 2024
Global Top Employer 2024 certification reflects Boehringer Ingelheim’s impactful people development
![Koropi groundbreaking](/sites/default/files/2024-01/Koropi%20groundbreaking.jpg)
January 11, 2024
Boehringer expands production site in Greece for new medicine
![Man with cat](/sites/default/files/2024-01/SENVELGO%20wins%20Best%20New%20Product%20for%20Companion%20Animals%20award%E2%80%8B.png)
January 10, 2024
SENVELGO® wins Best New Product for Companion Animals award
![Scientists/doctors looking on a tablet](/sites/default/files/2024-01/ADVANCE.jpg)
January 09, 2024
New study paves the way for liver cirrhosis treatments
![Discussion of doctors and caregivers](/sites/default/files/2024-01/JPM_summary.jpg)
January 09, 2024
Kicking off 2024 with five new R&D partnerships
![Kyowa](/sites/default/files/2024-01/Malin_Kyowa_1.jpg)
January 05, 2024
Boehringer Ingelheim licenses a new compound as part of its commitment to people living with fibro-inflammatory diseases from Kyowa Kirin
![Partnership 3T Bio Partnership 3T Bio](/sites/default/files/2024-01/Malin.png)
January 04, 2024
Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies
![Scientists in the lab](/sites/default/files/2024-01/PR_Ribo.png)
January 03, 2024
Partnership for new liver disease treatments with Ribo
![Huebler_Schmelmer Huebler_Schmelmer](/sites/default/files/2023-12/Huebler_Schmelmer.jpg)
December 18, 2023
Boehringer Ingelheim announces appointments Board of Managing Directors
![Doctors in a discussion](/sites/default/files/2023-11/IBM%20PRess.jpg)
November 28, 2023
Partnership with IBM to accelerate new antibody therapies
![Diabetic cat with owner](/sites/default/files/2023-11/Diabetic%20cat%20with%20owner.png)
November 23, 2023
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
![Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss](/sites/default/files/2023-11/BI_Workplace_Lab_Discussion-01_RGB_001%20%281%29.jpg)
November 22, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
![Asi+empa image.jpg](/sites/default/files/2023-11/Asi%2Bempa%20image.jpg)
November 03, 2023
Boehringer Ingelheim achieves major milestone in chronic kidney disease
![Life forward release 1](/sites/default/files/2023-10/MicrosoftTeams-image%20%2810%29.png)
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
![Prix Galien 2023.jpeg](/sites/default/files/2023-10/Prix%20Galien%202023.jpeg)
October 30, 2023
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
![Phase III trials_image.png](/sites/default/files/2023-10/Phase%20III%20trials_image.png)
October 05, 2023
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
![Woman and Man in Computer room](/sites/default/files/2023-10/AdobeStock_160945102.jpeg)
October 02, 2023
Partnership with Precision Health Research, Singapore
![Eye in detail](/sites/default/files/2023-10/CRD_PR.jpg)
October 02, 2023
Phase 1 start of treatment for Geographic Atrophy patients
October 02, 2023
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
![KMP_tree_ClimateSeed_Ⓒ Permian Global 1440 x 810 plus Copyright 460kb.jpg](/sites/default/files/2023-09/KMP_tree_ClimateSeed_%E2%92%B8%20Permian%20Global%201440%20x%20810%20plus%20Copyright%20460kb.jpg)
September 14, 2023
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
![Man with cattle herd](/sites/default/files/2023-08/Credits%20%40GALVmed%20Karel%20Prinsloo.jpg)
September 05, 2023
New partnership working on solutions to combat African animal trypanosomiasis
![Obesity release.png](/sites/default/files/2023-08/Obesity%20release.png)
August 17, 2023
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
![Man with cat on sofa](/sites/default/files/2023-08/FDA%20Approval%20Senvelgo.jpg)
August 14, 2023
Boehringer Ingelheim receives FDA approval for SENVELGO®: the first oral liquid medication for diabetes in cats
![HY 2023 press release image](/sites/default/files/2023-07/HY%202023%20press%20release%20image%20resized.jpg)
August 01, 2023
First half of 2023: strong growth and expansion in key therapy areas
July 28, 2023
FRONTLINE® wins Brand of the Year Award for the third time in a row
![Kidney Diseases Kidney Diseases](/sites/default/files/2023-07/hands%20%26%20kidney%20image_1280x720_v01%5B37%5D.jpg)
July 25, 2023
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
![Female veterinarian with dog in practise, woman and kid standing in background](/sites/default/files/2023-07/NexGard%20PLUS%2016x9.png)
July 20, 2023
Boehringer Ingelheim receives FDA approval for NexGard® PLUS: a beef-flavored soft chew that protects dogs from internal and external parasites
![A person touching a scientific data visualization](/sites/default/files/2023-07/MicrosoftTeams-image%20%286%29.png)
July 04, 2023
Spesolimab prevents GPP flares
![Scientist with tablet stock image](/sites/default/files/2023-06/Scientist%20with%20tablet.jpg)
June 23, 2023
Phase II trial data shows nearly 19% weight loss in people with overweight or obesity
![230622_CKD_CHMP_WebsiteCard_1440x810px.jpg](/sites/default/files/2023-06/230622_CKD_CHMP_WebsiteCard_1440x810px.jpg)
June 23, 2023
Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU
![Phase II trial results in people living with obesity or overweight](/sites/default/files/2023-05/shutterstock_1901403778.jpg%201440%20%C3%97%20810.jpg)
May 10, 2023
Phase II trial results in people living with obesity or overweight
![colorful picture](/sites/default/files/2023-05/FibroticDisease.jpg)
May 09, 2023
IL-11 inhibitor antibody clinical development launched
![SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares Finger pointing at a digital tick box](/sites/default/files/2023-05/Spesolimab%20Breakthrough%20Designation%20Press%20Release%20Image.jpg)
May 02, 2023
Breakthrough Designation granted in US and China
![Dreyer_vonBaumbach_Scholz Dreyer_vonBaumbach_Scholz](/sites/default/files/2023-05/MicrosoftTeams-image%20%283%29.png)
May 02, 2023
Boehringer and German Chancellor Olaf Scholz lay the foundation stone for EUR 285 million innovation center
![Einweihung BDC](/sites/default/files/2023-04/Einweihung%20BDC%2024.April%20resized.png)
April 24, 2023
Boehringer inaugurates largest European development centre for biotechnology
![ARPC press release](/sites/default/files/2023-03/069_%C2%A9%202020%2C%20Peter%20Ginter%20-%20inspection%20shovel%20dryer%20fro%20website%20.jpg)
March 29, 2023
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
![People standing in a circle in rural Africa](/sites/default/files/2023-02/LastMile%20Press%20Release%20Thumbnail.jpg)
March 02, 2023
LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
![A doctor speaks to a patient about results of medical checks whilst sat in a general practice A female doctor speaks to a male patient about results of medical checks whilst sat in a general practice](/sites/default/files/2023-01/Effisayil%202%20-GettyImages-1212860058%20resize.jpg)
January 30, 2023
Spesolimab meets key endpoint for GPP flare prevention
![Empa_Kidney](/sites/default/files/2023-01/shutterstock__Klein.jpg)
January 24, 2023
FDA accepts application for new CKD treatment
![Top Employer 2023 Top Employer 2023](/sites/default/files/2023-01/BI_1570.jpg)
January 17, 2023
Global Top Employer 2023
![monecules](/sites/default/files/2023-01/Teaser_3t.jpg)
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
![](/sites/default/files/Images/apc_2016_bic.jpg)
December 20, 2022
Boehringer Ingelheim announces appointments to Board of Managing Directors
![woman with mobilephone](/sites/default/files/2022-12/ClickTxTeaser.png)
December 19, 2022
New digital Tx collab with Click
![EC grants marketing authorization for spesolimab](/sites/default/files/2022-12/786212587-009_400x400px_cc01.jpg)
December 13, 2022
EC grants conditional marketing authorization for spesolimab
![New positive data in Phase III type 2 diabetes trial](/sites/default/files/2022-12/shutterstock_1021932094.jpg)
December 07, 2022
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
![EMPA-KIDNEY trial meets primary endpoint EMPA-KIDNEY trial meets primary endpoint](/sites/default/files/2022-11/BI%20Kidney%20image_1920x1080px_0.jpg)
November 04, 2022
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
![Tree shaped as lungs with the press release title On the left side of the image is the label which reads #Press’. Under the label is the text which reads First Patient enrolled in FIBRONEER-IPF Phase III trial. The right side of the image shows a tree shaped as lungs](/sites/default/files/2022-10/BI.com%20Post%20Release.jpg)
October 26, 2022
FIBRONEER™ Phase III program initiated in over 40 countries
![AI&Data Science Fellowship Tuebingen](/sites/default/files/2022-10/Tue%20Fellowship%20prog.jpg)
October 20, 2022
AI and Data Science Fellowship with University of Tuebingen
![Scientific laboratory staff member wearing a lab coat looks into a microscope Female scientific laboratory staff member wearing a lab coat uses a microscope by staring into it](/sites/default/files/2022-10/CHMP%20Upload%20form%20image_1440x810_CC02.jpg)
October 14, 2022
CHMP recommends conditional approval for first GPP treatment
![The 2022 PRRS Award Winners Collage of four individual headshots, three men, one woman](/sites/default/files/2022-09/PRRS%20Awards%202022%20Thumbnail%20%282%29.png)
October 10, 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
![Cowtribe in action](/sites/default/files/2022-09/20200823_112854.jpg)
October 05, 2022
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
![Birth of a calf](/sites/default/files/2022-09/335A4008.jpg)
September 06, 2022
Boehringer Ingelheim launches Fencovis®, a new vaccine to prevent calf diarrhea
![New Phase III data in children living with ILD New Phase III data in children living with ILD](/sites/default/files/2022-09/InPedILD_ERS_press_release.jpg)
September 05, 2022
New data for nintedanib in children with fibrosing interstitial lung disease
![Person holds scientific breakthrough in their hands Businessman using digital x-ray human body scan interface 3D rendering](/sites/default/files/2022-09/Image-for-FDA-Press-release_1440x810px.jpg)
September 02, 2022
First approval for SPEVIGO® to treat GPP flares
![People working in a lab](/sites/default/files/2022-08/16%209%20size%20People%20working%20in%20a%20lab.jpg)
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
![Small group of female laboratory assistants checking blood, using microscope and doing tests](/sites/default/files/2022-06/16%209%20size%20Small%20group%20of%20female%20laboratory%20assistants%20checking%20blood%2C%20using%20microscope%20and%20doing%20tests.jpg)
July 06, 2022
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
![T-cell 1440_810.png](/sites/default/files/2022-06/T-cell%201440_810.png)
June 14, 2022
Option to Acquire Trutino Biosciences
![Vet examining dog Vet examining dog](/sites/default/files/2022-05/China_MG_4648.jpg)
June 14, 2022
Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology
![Medical worker showing a heart](/sites/default/files/2022-06/EMPRISE_website_card_image_16_9.jpg)
June 06, 2022
Jardiance® (empagliflozin) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
![A*Star](/sites/default/files/2022-06/thumbnail.jpg)
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
![Learn about our latest investigational treatment that slowed lung function decline in people with IPF Visual representation of human lungs](/sites/default/files/2022-05/786212706-002_BI_PF_ATS_Press-Release_Social_1920x1080_CC03_image-only_0.jpg)
May 15, 2022
Investigational treatment slowed lung function decline in IPF
![Man injects piglet with vaccines that have been mixed in TwistPak](/sites/default/files/2022-05/TwistPak%20hero%20image.jpg)
May 12, 2022
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
![AI machine deep learning.jpg](/sites/default/files/2022-05/AI%20machine%20deep%20learning.jpg)
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
![A woman rides a horse A woman rides a horse](/sites/default/files/2022-04/RenuTend%20visual.png)
April 21, 2022
Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses
![048_© 2020, Peter Ginter - final adjustments at the “pipe crossover”](/sites/default/files/2022-04/048_%C2%A9%202020%2C%20Peter%20Ginter%20-%20final%20adjustments%20at%20the%20%E2%80%9Cpipe%20crossover%E2%80%9D%20resized.png)
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
![data](/sites/default/files/2022-03/Data.jpg)
March 29, 2022
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
![Urban girl standing out from the crowd at a city street.](/sites/default/files/2022-03/AAD%20press%20release%20supporting%20image_resized.png)
March 28, 2022
New spesolimab data show significant improvement in GPP flares
![Cows in stable](/sites/default/files/2022-03/_15A3705_0.jpg)
March 22, 2022
Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being
![EMPA-KIDNEY](/sites/default/files/2022-03/220316_EMPA-KIDNEY_Early-Stop_0.jpg)
March 16, 2022
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
![EMA_PressRelease](/sites/default/files/2022-03/EMA_website_teaser_card_16_9.jpg)
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
![Patient and Doctor talking to each other. You can only see their hands](/sites/default/files/2022-03/EMPULSE_Image_2_Doctor_Patient.jpg)
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
![Data digital](/sites/default/files/2022-02/400x400smallformat_Digital1.jpg)
March 01, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
![Hands holding a heart](/sites/default/files/2022-02/FDA_website_teaser_card_16_9.jpg)
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
![White lung shown on mint background](/sites/default/files/2022-02/786212575-009_BI_IPF_FDA%20Asset_1440X810_CC01-01.jpg)
February 24, 2022
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
![Cattle herd](/sites/default/files/2022-01/black%20cow%202.jpg)
February 09, 2022
New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows
![Heardbeat in context of heart failure](/sites/default/files/2022-02/CHMP_website_teaser_card_16_9.jpg)
January 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
![Top Employer](/sites/default/files/2022-01/Mediapool_TopEmployer2022%20%281%29.jpg)
January 20, 2022
Award: Boehringer Ingelheim is Global Top Employer 2022
![Immunology](/sites/default/files/2022-01/400x400smallformat_Immuno.jpg)
January 18, 2022
Collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
![GPP_Press_Release](/sites/default/files/2021-12/Supporting%20press%20release%20image.png)
December 23, 2021
Spesolimab Phase II data
![FDA Press Release](/sites/default/files/2021-12/211213%20FDA%20Press%20Release%20Image_1440x810_72dpi_cc01.jpg)
December 15, 2021
U.S. FDA grants priority review for spesolimab in GPP
![BISE_Bungoma_County.jpg](/sites/default/files/2021-12/BISE_Bungoma_County.jpg)
November 11, 2021
Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
![Making-more-health-together-2021 Making-more-health-together-2021](/sites/default/files/2023-03/MMHT_visual.jpg)
November 11, 2021
Making More Health Together 2021: Creating sustainable health solutions for 50 million people in vulnerable communities
![](/sites/default/files/Images/press-release-holding-image02.jpg)
November 06, 2021
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
![commitments to sustainable development commitments to sustainable development](/sites/default/files/2023-03/More%20Potential_Picture%20for%20Tweet.jpg)
November 03, 2021
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
![environmental sustainability commitments environmental sustainability commitments](/sites/default/files/2023-03/MoreGreenCard_400x400px.jpeg)
November 01, 2021
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
![](/sites/default/files/Images/press-release-holding-image03.jpg)
October 29, 2021
EMA validates spesolimab marketing authorization application in GPP
![opening-solids-launch-fabrik opening-solids-launch-fabrik](/sites/default/files/2023-03/Kachelbild%20SOL_11zon.jpeg)
October 27, 2021
Boehringer Ingelheim opens high-tech tablet production facility in Ingelheim
![collaboration-kings-college-london collaboration-kings-college-london](/sites/default/files/2023-03/AdobeStock_KCL.jpeg)
October 27, 2021
Mental health collaboration with King’s College London
![Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy](/sites/default/files/2023-03/cardpic.jpeg)
October 26, 2021
Partnership to Develop Urea Cycle Disorders Therapy
![BI increases commitments to sustainable development BI increases commitments to sustainable development](/sites/default/files/2023-03/MIR_I_klein.jpg)
October 25, 2021
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
![Use of Aservo EquiHaler in horse Use of Aservo EquiHaler in horse](/sites/default/files/Animal_Health/EquiHaler_001_2019-08-27_exhale_5790_0.jpg)
October 20, 2021
Aservo® EquiHaler® wins 2021 Pharmapack Award
![Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise](/sites/default/files/2023-03/AdobeStock_Woman_OxygenMask.jpeg)
October 19, 2021
Cystic Fibrosis Gene Therapy Takes to Next step
![](/sites/default/files/Images/press-release-holding-image01.jpg)
October 12, 2021
Boehringer Ingelheim Launches University of Medicine Excellence
![This year, Prof. Boaz Arzi from University of California, Davis, has won the Company’s first Translational Medicine Award.](/sites/default/files/2021-12/BI%20TMA%20award%202021_3%20%28005%29.png)
October 11, 2021
Boehringer Ingelheim awards its first Translational Medicine Award
![additional-investment-in-Lyon-Jonage additional-investment-in-Lyon-Jonage](/sites/default/files/2023-03/Lyon-Jonage%20.jpg)
October 08, 2021
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
![inauguration_biopharmaceutical_production_facility_vienna inauguration_biopharmaceutical_production_facility_vienna](/sites/default/files/2023-03/LSCC_Kachelbild.jpg)
October 06, 2021
Boehringer Ingelheim inaugurates biopharmaceutical production facility in Vienna, Austria
![WRD press release hand holds paws WRD press release hand holds paws](/sites/default/files/Animal_Health/WRD%20press%20release%20tile%20image%20option%202.png)
September 28, 2021
World Rabies Day: fighting rabies misconceptions
![Research and development Research and development](/sites/default/files/Animal_Health/Reserach%20and%20development.png)
September 27, 2021
Boehringer Ingelheim and Invetx announce strategic collaboration
![2021 European PRRS Research Award winners.png 2021 European PRRS Research Award winners.png](/sites/default/files/2022-04/2021%20European%20PRRS%20Research%20Award%20winners.png)
September 23, 2021
2021 European PRRS Research Award winners announced
![Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology](/sites/default/files/2023-03/shutterstock_274014893_0.jpg)
September 21, 2021
Acquisition to advance cancer immunology research
![clinical-collaboration-with-Amgen clinical-collaboration-with-Amgen](/sites/default/files/2023-03/WebsiteCard.jpg)
September 16, 2021
Clinical collaboration with Amgen on KRAS
![Swine in stable Swine in stable](/sites/default/files/Animal_Health/Brazil_IMG_7057_400.jpg)
September 15, 2021
Positive opinion for combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU®
September 13, 2021
FRONTLINE® becomes Brand of the Year 2021-22
![](/sites/default/files/Images/press-release-holding-image01.jpg)
September 09, 2021
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
![](/sites/default/files/Images/press-release-holding-image03.jpg)
September 09, 2021
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
![](/sites/default/files/Images/press-release-holding-image01.jpg)
August 27, 2021
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
![Boehringer-Ingelheim's-half-year-figures-2021 Boehringer-Ingelheim's-half-year-figures-2021](/sites/default/files/2023-03/Pressebild_Boehringer_Ingelheim_0.jpeg)
August 03, 2021
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
![](/sites/default/files/Images/press-release-holding-image01.jpg)
July 26, 2021
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
![Odile Bain Memorial Prize 2021 Odile Bain Memorial Prize 2021](/sites/default/files/Animal_Health/Odile%20Bain%20Prize_400.jpg)
July 21, 2021
Odile Bain Memorial Prize recognizes brilliant research in parasitology
![Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim](/sites/default/files/2023-03/248400545-2.jpg)
July 16, 2021